Your browser doesn't support javascript.
loading
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee, Elizabeth K; Xiong, Niya; Cheng, Su-Chun; Barry, William T; Penson, Richard T; Konstantinopoulos, Panagiotis A; Hoffman, Mark A; Horowitz, Neil; Dizon, Don S; Stover, Elizabeth H; Wright, Alexi A; Campos, Susana M; Krasner, Carolyn; Morrissey, Stephanie; Whalen, Christin; Quinn, Roxanne; Matulonis, Ursula A; Liu, Joyce F.
Affiliation
  • Lee EK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Xiong N; Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Cheng SC; Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Barry WT; Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Penson RT; Department of Medical Gynecologic Oncology, Massachusetts General Hospital, Boston, MA, United States of America.
  • Konstantinopoulos PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Hoffman MA; Long Island Jewish Medical Center, New Hyde Park, NY, United States of America.
  • Horowitz N; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America; Department of Obstetrics & Gynecology, Brigham & Women's Hospital, Boston, MA, United States of America.
  • Dizon DS; Brown University, Division of Women's Cancers, Lifespan Cancer Institute, Providence, RI, United States of America.
  • Stover EH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Wright AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Campos SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Krasner C; Department of Medical Gynecologic Oncology, Massachusetts General Hospital, Boston, MA, United States of America.
  • Morrissey S; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Whalen C; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Quinn R; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America. Electronic address: Ursula_Matulonis@dfci.harvard.edu.
  • Liu JF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America. Electronic address: Joyce_Liu@dfci.harvard.edu.
Gynecol Oncol ; 159(1): 72-78, 2020 10.
Article in En | MEDLINE | ID: mdl-32771276
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Doxorubicin / Antibodies, Monoclonal, Humanized / Carcinoma, Ovarian Epithelial Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Aged / Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2020 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Doxorubicin / Antibodies, Monoclonal, Humanized / Carcinoma, Ovarian Epithelial Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Limits: Aged / Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2020 Type: Article Affiliation country: United States